Please assess the completion status of the following clinical trial:

Trial Title: Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of SPMS~* Age 40-70 years~* Able to understand English and able to give informed consent~Exclusion Criteria:~* Unable to undergo MRI testing~* For ambulatory subjects only, a self-reported medical or neurological condition other than MS that is a cause of progressive or fluctuating problems that affect walking(e.g. worsening neuropathy, uncontrolled lower extremity arthritis, uncontrolled heart or lung disease)~* For ambulatory subjects only, fixed and/or stable conditions of less than 1 years duration that affect walking (e.g. joint replacement, lumbar stenosis, alcoholism, stroke, etc.)~* Pregnant or breast-feeding.~* Current major disease or disorder other than MS (such as cancer, kidney, heart or lung disease, post-traumatic stress disorder) that may interfere with study procedures~* Natalizumab, mitoxantrone, azathioprine taken in the last 12 months~* Other immunosuppressants or chemotherapies taken in the last 12 months~* Scheduled (every 3 months or more frequently) IV steroids used in the last 12 months~* IV or oral steroids taken in the past 60 days.~* Lipoic acid taken in the past 60 days.~* Subject has insulin-dependent diabetes or is not controlled on oral diabetes medications

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: lipoic acid (Type: EXPERIMENTAL): 28 subjects receive oral lipoic acid 1200mg daily
- Arm 2: placebo (Type: PLACEBO_COMPARATOR): 28 subjects receive placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).